Professional Documents
Culture Documents
The following database contains a listing of drugs approved by the Food and Drug Administration (FDA)
for sale in the United States. Drug information typically includes the drug name, approval status,
indication of use, and clinical trial results. Review descriptions for our medical therapeutic area list to
help assist in your search.
Dermatology
Ilumya (tildrakizumab-asmn); Sun Pharmaceuticals; For the treatment of plaque psoriasis , Approved
March 2018
Libtayo (cemiplimab-rwlc); Regeneron Pharmaceuticals; For the treatment of cutaneous squamous cell
carcinoma, Approved September 2018
Seysara (sarecycline) ; Paratek Pharmaceuticals; For the treatment of moderate to severe acne vulgaris in
patients 9 years of age and older., Approved October 2018
Family Medicine
Aimovig (erenumab-aooe) ; Amgen; For the preventive treatment of migraine in adults , Approved May
2018
Ajovy (fremanezumab-vfrm); Teva Pharmaceuticals; For the treatment of migraine, Approved September
2018
Xofluza (baloxavir marboxil); Shionogi; For the treatment of acute uncomplicated influenza , Approved
October 2018
Gastroenterology
Aemcolo (rifamycin); Aries Pharmaceuticals; For the treatment of traveler's diarrhea, Approved
November 2018
Lutathera (lutetium Lu 177 dotatate); Advanced Accelerator Applications; For the treatment of
gastroenteropancreatic neuroendocrine tumors, Approved January 2018
Genetic Disease
Galafold (migalastat); Amicus Therapeutics; For the treatment of Fabry Disease, Approved August 2018
Onpattro (patisiran); Alnylam Pharmaceuticals; For the treatment of the polyneuropathy of hereditary
transthyretin-mediated amyloidosis in adults, Approved August 2018
Revcovi (elapegademase-lvlr); Leadiant Biosciences; For the treatment of adenosine deaminase severe
combined immune deficiency, Approved October 2018
Tegsedi (inotersen); Ionis Pharmaceuticals; For the treatment of the polyneuropathy of hereditary
transthyretinmediated amyloidosis in adults, Approved October 2018
Hematology
Copiktra (duvelisib); Verastem; For the treatment of chronic lymphocytic leukemia, small lymphocytic
lymphoma or follicular lymphoma, Approved September 2018
Daurismo (glasdegib); Pfizer; For the treatment of newly-diagnosed acute myeloid leukemia in adults 75
years of age or older , Approved November 2018
Doptelet (avatrombopag) ; AkaRx; For the treatment of thrombocytopenia in adults with chronic liver
disease scheduled to undergo a procedure, Approved May 2018
Jivi (antihemophilic factor [recombinant] PEGylated-aucl); Bayer; For hemophilia A, Approved August
2018
Lokelma (sodium zirconium cyclosilicate); AstraZeneca; For the treatment of hyperkalemia, Approved
May 2018
Lumoxiti (moxetumomab pasudotox-tdf); AstraZeneca; For the treatment of relapsed or refractory hairy
cell leukemia, Approved September 2018
Mulpleta (lusutrombopag); Shionogi; For the treatment of thrombocytopenia in adults with chronic liver
disease scheduled to undergo a procedure, Approved August 2018
Palynziq (pegvaliase-pqpz) ; BioMarin; For the treatment of phenylketonuria, Approved May 2018
Poteligeo (mogamulizumab-kpkc); Kyowa Kirin; For the treatment of mycosis fungoides or Sézary
syndrome , Approved August 2018
Tavalisse (fostamatinib disodium hexahydrate); Rigel Pharmaceuticals; For the treatment of chronic
immune thrombocytopenia, Approved April 2018
Tibsovo (ivosidenib); Agios Pharmaceuticals; For the treatment of acute myeloid leukemia with a
susceptible IDH1 mutation, Approved July 2018
Xospata (gilteritinib) ; Astellas; For the treatment of acute myeloid leukemia with a FLT3 mutation,
Approved November 2018
Mulpleta (lusutrombopag); Shionogi; For the treatment of thrombocytopenia in adults with chronic liver
disease scheduled to undergo a procedure, Approved August 2018
Immunology
Ilumya (tildrakizumab-asmn); Sun Pharmaceuticals; For the treatment of plaque psoriasis , Approved
March 2018
Revcovi (elapegademase-lvlr); Leadiant Biosciences; For the treatment of adenosine deaminase severe
combined immune deficiency, Approved October 2018
Tavalisse (fostamatinib disodium hexahydrate); Rigel Pharmaceuticals; For the treatment of chronic
immune thrombocytopenia, Approved April 2018
Xofluza (baloxavir marboxil); Shionogi; For the treatment of acute uncomplicated influenza , Approved
October 2018
Yupelri (revefenacin); Theravance Biopharma; For the maintenance treatment of chronic obstructive
pulmonary disease, Approved November 2018
Aemcolo (rifamycin); Aries Pharmaceuticals; For the treatment of traveler's diarrhea, Approved
November 2018
Delstrigo (doravirine, lamivudine, and tenofovir disoproxil fumarate) ; Merck; For the treatment of HIV-1
infection, Approved August 2018
Pifeltro (doravirine) ; Merck; For the treatment of HIV-1 infection, Approved August 2018
Symtuza (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide); Janssen Therapeutics; For the
treatment of HIV-1 infection, Approved July 2018
Tpoxx (tecovirimat); Siga Technologies; For the treatment of smallpox , Approved July 2018
Trogarzo (ibalizumab-uiyk); TaiMed Biologics; For the treatment of multidrug resistant HIV-1 infection,
Approved March 2018
Xerava (eravacycline) ; Tetraphase Pharmaceuticals; For the treatment of complicated intra-abdominal
infections , Approved August 2018
Xofluza (baloxavir marboxil); Shionogi; For the treatment of acute uncomplicated influenza , Approved
October 2018
Internal Medicine
Tegsedi (inotersen); Ionis Pharmaceuticals; For the treatment of the polyneuropathy of hereditary
transthyretinmediated amyloidosis in adults, Approved October 2018
Musculoskeletal
Nephrology
Jynarque (tolvaptan); Otsuka America; For the treatment of autosomal dominant polycystic kidney
disease, Approved April 2018
Neurology
Aimovig (erenumab-aooe) ; Amgen; For the preventive treatment of migraine in adults , Approved May
2018
Ajovy (fremanezumab-vfrm); Teva Pharmaceuticals; For the treatment of migraine, Approved September
2018
Diacomit (stiripentol) ; Biocodex; For the treatment of seizures associated with Dravet syndrome,
Approved August 2018
Dsuvia (sufentanil) ; AcelRx Pharma; For the management of acute pain, Approved November 2018
Emgality (galcanezumab-gnlm) ; Eli Lilly; For the preventive treatment of migraine in adults , Approved
September 2018
Onpattro (patisiran); Alnylam Pharmaceuticals; For the treatment of the polyneuropathy of hereditary
transthyretin-mediated amyloidosis in adults, Approved August 2018
Tegsedi (inotersen); Ionis Pharmaceuticals; For the treatment of the polyneuropathy of hereditary
transthyretinmediated amyloidosis in adults, Approved October 2018
Bijuva (estradiol and progesterone) ; TherapeuticsMD; For the treatment of moderate to severe
vasomotor symptoms due to menopause, Approved October 2018
Talzenna (talazoparib); Pfizer; For the treatment of deleterious germline BRCA-mutated HER2-negative
locally advanced or metastatic breast cancer, Approved October 2018
Oncology
Copiktra (duvelisib); Verastem; For the treatment of chronic lymphocytic leukemia, small lymphocytic
lymphoma or follicular lymphoma, Approved September 2018
Daurismo (glasdegib); Pfizer; For the treatment of newly-diagnosed acute myeloid leukemia in adults 75
years of age or older , Approved November 2018
Erleada (apalutamide); Janssen Oncology; For the treatment of prostate cancer, Approved February 2018
Libtayo (cemiplimab-rwlc); Regeneron Pharmaceuticals; For the treatment of cutaneous squamous cell
carcinoma, Approved September 2018
Lorbrena (lorlatinib); Pfizer; For the treatment of ALK-positive metastatic non-small cell lung cancer ,
Approved November 2018
Lumoxiti (moxetumomab pasudotox-tdf); AstraZeneca; For the treatment of relapsed or refractory hairy
cell leukemia, Approved September 2018
Lutathera (lutetium Lu 177 dotatate); Advanced Accelerator Applications; For the treatment of
gastroenteropancreatic neuroendocrine tumors, Approved January 2018
Poteligeo (mogamulizumab-kpkc); Kyowa Kirin; For the treatment of mycosis fungoides or Sézary
syndrome , Approved August 2018
Talzenna (talazoparib); Pfizer; For the treatment of deleterious germline BRCA-mutated HER2-negative
locally advanced or metastatic breast cancer, Approved October 2018
Tibsovo (ivosidenib); Agios Pharmaceuticals; For the treatment of acute myeloid leukemia with a
susceptible IDH1 mutation, Approved July 2018
Vitrakvi (larotrectinib); Loxo Oncology; For the treatment of solid tumors that have a neurotrophic
receptor tyrosine kinase (NTRK) gene fusion, Approved November 2018
Vizimpro (dacomitinib); Pfizer; For the treatment of metastatic non-small cell lung cancer , Approved
September 2018
Xospata (gilteritinib) ; Astellas; For the treatment of acute myeloid leukemia with a FLT3 mutation,
Approved November 2018
Ophthalmology
Pediatrics/Neonatology
Diacomit (stiripentol) ; Biocodex; For the treatment of seizures associated with Dravet syndrome,
Approved August 2018
Pharmacology/Toxicology
Lucemyra (lofexidine); US Worldmeds; For the mitigation of opioid withdrawal symptoms to facilitate
abrupt opioid discontinuation in adults, Approved May 2018
Pulmonary/Respiratory Diseases
Lorbrena (lorlatinib); Pfizer; For the treatment of ALK-positive metastatic non-small cell lung cancer ,
Approved November 2018
Nuzyra (omadacycline) ; Paratek Pharmaceuticals; For the treatment of community-acquired bacterial
pneumonia and acute bacterial skin and skin structure infections, Approved October 2018
Symdeko (tezacaftor/ivacaftor) ; Vertex; For the treatment of cystic fibrosis , Approved February 2018
Vizimpro (dacomitinib); Pfizer; For the treatment of metastatic non-small cell lung cancer , Approved
September 2018
Yupelri (revefenacin); Theravance Biopharma; For the maintenance treatment of chronic obstructive
pulmonary disease, Approved November 2018
Urology
Erleada (apalutamide); Janssen Oncology; For the treatment of prostate cancer, Approved February 2018